Why Astrazeneca (AZN) is a Top Growth Stock for the Long-Term

According to Zacks Investment Research, AstraZeneca (AZN) is a stock to watch for growth investors, holding a Zacks Rank of #3 (Hold) but possessing a VGM Score of A and a Growth Style Score of B. The company's year-over-year earnings are projected to grow by 9.3% for the current fiscal year, and the Zacks Consensus Estimate for fiscal 2025 has increased to $4.49 per share following upward revisions by two analysts.

Analysis

AstraZeneca (AZN) presents a compelling case for growth-oriented investors, according to the provided Zacks Investment Research analysis, despite its current Zacks Rank of #3 (Hold). This assessment is primarily driven by its strong ancillary metrics: a VGM Score of A and a Growth Style Score of B. The biopharmaceutical company is projected to achieve a significant 9.3% year-over-year earnings growth for the current fiscal year. Further bolstering this outlook, two analysts have revised their earnings estimates upwards for fiscal 2025, with the Zacks Consensus Estimate for that period now standing at $4.49 per share. AZN has also demonstrated a pattern of outperforming expectations, evidenced by an average earnings surprise of 4.2%. The sentiment surrounding these company-specific fundamentals is strongly positive (overall sentiment score 0.75, AZN specific sentiment 0.8) with an optimistic tone, although the broader market impact of this particular analysis is rated as moderate (0.35). The article frames these strong growth indicators and positive analyst revisions as reasons AZN should be on investors' shortlists, particularly those prioritizing growth, even with a neutral primary rank.

Key Decisions for Investors

• Growth-focused investors should consider AZN's robust 9.3% projected earnings growth, its 'A' VGM Score, and 'B' Growth Style Score as significant positive indicators, despite the current Zacks #3 (Hold) rating.
• Investors should monitor for any potential upgrades in AZN's Zacks Rank; a shift to #1 (Strong Buy) or #2 (Buy) would, according to the Zacks methodology highlighted, substantially strengthen the investment case when combined with its existing A or B Style Scores.
• While the growth metrics and 4.2% average earnings surprise are encouraging, the 'Hold' rating suggests a balanced approach; further due diligence on valuation, pipeline developments, and sector-specific factors is warranted before making significant allocation changes.